Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

321.91
2,355,150

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 5:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amgen Files for Xgeva Label Expansion, To Include Myeloma

by Zacks Equity Research

Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.

    Arpita Dutt headshot

    Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug

    by Arpita Dutt

    Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.

      Why Is Amgen (AMGN) Up 12.9% Since the Last Earnings Report?

      by Zacks Equity Research

      Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Kite Pharma Completes Filing for CAR-T Therapy with FDA

        by Zacks Equity Research

        Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.

          Mylan Receives CRL for Generic Advair Diskus From the FDA

          by Zacks Equity Research

          Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.

            Amgen's Leukemia Drug Accepted for Priority Review by FDA

            by Zacks Equity Research

            Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.

              Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

              by Zacks Equity Research

              Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

                J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe

                by Zacks Equity Research

                Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).

                  Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

                  by Zacks Equity Research

                  Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).

                    Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval

                    by Zacks Equity Research

                    Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.

                      The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General Electric and Carnival

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General Electric and Carnival

                        Sheraz Mian headshot

                        Stock Research Reports for Amgen, Berkshire & Walgreens

                        by Sheraz Mian

                        Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Amgen, Inc. (AMGN) and Walgreens Boots Alliance Inc (WBA).

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

                          by Arpita Dutt

                          Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

                            Arpita Dutt headshot

                            3 Biotech Stocks That Are Broker Favorites

                            by Arpita Dutt

                            These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).

                              Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

                              by Zacks Equity Research

                              Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

                                What are Sanofi's (SNY) Strengths and Challenges in 2017?

                                by Zacks Equity Research

                                We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.

                                  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

                                  by Zacks Equity Research

                                  Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

                                    Does Amgen Offer a Great Value Buying Opportunity Right Now?

                                    by Zacks Equity Research

                                    Is Amgen a great pick from the value Investor's perspective right now? Read on to know more.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

                                      by Arpita Dutt

                                      The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

                                        Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication

                                        by Zacks Equity Research

                                        Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.

                                          Amgen's Repatha Meets Primary Endpoint in Phase III Study

                                          by Zacks Equity Research

                                          Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).

                                            Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?

                                            by Zacks Equity Research

                                            Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.

                                              J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day

                                              by Zacks Equity Research

                                              J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day

                                                Novartis (NVS) Reports Positive Data on Biosimilar Humira

                                                by Zacks Equity Research

                                                Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.

                                                  Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View

                                                  by Zacks Equity Research

                                                  Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.